Breast Cancer

BioLucent, Inc. has received 510(k)clearance from the FDA for its SAVIapplicator. The SAVI device offersa multicatheter, single-entry approachto breast brachytherapy.

A multinationalphase II study, known as CHAT,has shown that a three-drug combinationincluding docetaxel (Taxotere),trastuzumab (Herceptin), and capecitabine(Xeloda) provides significantlylonger time to progression (TTP) and atrend toward longer progression-free survival,compared with docetaxel plustrastuzumab, in patients with HER2-positivemetastatic breast cancer.

So-called "DES daughters," born to mothers who used the antimiscarriage drug diethylstilbestrol (DES) during pregnancy, are at a substantially greater risk of developing breast cancer compared to women who were not exposed to the drug in utero.

Cytogen Corporation recently announced that Soltamox (tamoxifen citrate, oral solution 10 mg/5 mL), the first liquid form of the hormonal breast cancer therapy tamoxifen, is currently being introduced in the United States and is available in US pharmacies nationwide.

Women who reported the highest levels of physical activity in the year before they were diagnosed with breast cancer may have higher survival

The science supporting molecularly targeted therapies for the treatment of patients with solid tumors continues to evolve. Nurses are challenged to understand cell signaling, molecular targeting, and the mechanism of action of targeted agents. Two cell signal transduction pathways regulate the development, proliferation, and metastasis of solid tumors: the human epidermal growth factor (HER) receptor pathway and the vascular endothelial growth factor (VEGF) receptor pathway. Several novel pharmacologic agents with distinct indications and methods of administration target the HER and VEGF molecular pathways.

a brief overview of the dosing and administration guidelines for the various targeted therapy agents discussed in this supplement to the ONCOLOGY Nurse Edition. Please consult the manufacturer's package insert for more information.

Attendees at the 42nd Annual Meeting of the American Society of Clinical Oncology were eager to learn whether calcium and vitamin D supplementation has beneficial effects on breast cancer, mammograms, and arthralgias.

The risk reduction for breast and ovarian cancer associated with salpingo-oophorectomy (SO) in high-risk women varies according to the type of BRCA mutation,

GlaxoSmith-Kline (GSK) has announced the submission of a New Drug Application to the US Food and Drug Administration (FDA) for approval to market Tykerb (lapatinib ditosylate), in combination with capecitabine (Xeloda), for the treatment of advanced or metastatic HER2-positive breast cancer

The Oncologic Drugs Advisory Committee (ODAC) has recommended that FDA work with Abraxis Bioscience to design a well-controlled, randomized, reasonably sized clinical trial of Abraxane-paclitaxel protein-bound particles for injectable suspension (albumin bound)—to support a future supplemental application for the drug as an alternative to standard paclitaxel (Taxol) in the adjuvant treatment of node-positive breast cancer.

a new treatment model for breast cancer to reverse the eventual development of resistance to antiestrogen therapy, including an intriguing strategy that involves the use of very small doses of estrogen itself

Results of the multicenter Italian phase III Taxit 216 trial show marginally better disease-free survival (DFS) with the addition of sequential docetaxel (Taxotere) to standard epirubicin→CMF (cyclophosphamide/methotrexate/fluorouracil) as adjuvant treatment for high-risk early breast cancer, with acceptable toxicity.

Investigators continue to seek participants in an unusual breast cancer epidemiologic study. Rather than recruit the traditional pool of adult women, the Environmental and Genetic Determinants of Puberty study hopes to accrue 1,200 girls age 6 to 8, to examine the relationships among breast development, age at first menses, and factors such as hormonal changes, diet, exercise, obesity, family medical history, psychosocial stressors, environmental exposures, and genetic characteristics and biomarkers.

Although several studies of breast-conserving treatment have been conducted in women with multicentric or multifocal breast cancer, mastectomy is still the standard of care for this patient population

Before it will consider Genentech's supplemental Biologics License Application (sBLA) for Avastin (bevacizumab) plus chemotherapy as first-line treatment of metastatic breast cancer

Certain breast cancer risk factors vary by tumor histology and grade, according to a new analysis of data from the Breast Cancer Detection Demonstration Project Follow-Up Study

As half of all breast cancers occur in patients beyond the age of 65 and a quarter beyond the age of 75, a significant number of patients with metastatic breast cancer are elderly. New hormonal therapies, such as aromatase inhibitors, appear to have favorably improved the survival of these patients. Side effects such as osteoporosis or cognitive issues appear manageable. Information specific to elderly patients has recently emerged in the field of chemotherapy for metastatic breast cancer. This article reviews data on anthracyclines, taxanes, capecitabine (Xeloda), gemcitabine (Gemzar), trastuzumab (Herceptin), and bevacizumab (Avastin). For most patients in this setting, sequential single-agent chemotherapy appears at this time to be the preferred course of treatment.

As half of all breast cancers occur in patients beyond the age of 65 and a quarter beyond the age of 75, a significant number of patients with metastatic breast cancer are elderly. New hormonal therapies, such as aromatase inhibitors, appear to have favorably improved the survival of these patients. Side effects such as osteoporosis or cognitive issues appear manageable. Information specific to elderly patients has recently emerged in the field of chemotherapy for metastatic breast cancer. This article reviews data on anthracyclines, taxanes, capecitabine (Xeloda), gemcitabine (Gemzar), trastuzumab (Herceptin), and bevacizumab (Avastin). For most patients in this setting, sequential single-agent chemotherapy appears at this time to be the preferred course of treatment.

Women who reported the highest levels of physical activity in the year before they were diagnosed with breast cancer may have higher survival, according to a new study.

Fox Chase Cancer Center's V. Craig Jordan, OBE, PHD, DSC, has received a $10.7 million grant from the Department of Defense (DoD) Breast Cancer Research Program for a Breast Cancer Center of Excellence focused on developing a new treatment model for breast cancer to reverse the eventual development of resistance to antiestrogen therapy.

Astudy conducted by researchers from the Medical University of South Carolina (MUSC) and University of South Carolina shows that the cancer rate among blacks living in South Carolina is nearly twice as great as it is for whites in the state.

October is National Breast Cancer Awareness Month, a good time to briefly reflect on what cancer "awareness" means to the oncology community and to the growing number of breast cancer survivors nationwide

As half of all breast cancers occur in patients beyond the age of 65 and a quarter beyond the age of 75, a significant number of patients with metastatic breast cancer are elderly. New hormonal therapies, such as aromatase inhibitors, appear to have favorably improved the survival of these patients. Side effects such as osteoporosis or cognitive issues appear manageable. Information specific to elderly patients has recently emerged in the field of chemotherapy for metastatic breast cancer. This article reviews data on anthracyclines, taxanes, capecitabine (Xeloda), gemcitabine (Gemzar), trastuzumab (Herceptin), and bevacizumab (Avastin). For most patients in this setting, sequential single-agent chemotherapy appears at this time to be the preferred course of treatment.

Individualized cognitive therapy (CT) is effective in reducing depression in women with metastatic breast cancer

Postmenopausal women who take anastrozole (Arimidex) for 5 years as adjuvant therapy for breast cancer experience a 6% to 8% reduction in bone mineral density (BMD) in the lumbar spine and hip

Clinical trials may be running out of volunteers, according to a report at the American Society of Clinical Oncology 2006 meeting

The bone loss associated with adjuvant exemestane (Aromasin) therapy for breast cancer tends to be greater in women who have suboptimal levels of vitamin D

Although most American adults can identify mammography, the Pap test, and colonoscopy as cancer screening tests, they are generally ill informed about the age at which screening should begin and how often they should undergo the examinations.

Combining the investigational aromatase inhibitor atamestane with the estrogen-blocker toremifene (Fareston) in an attempt to achieve "complete estrogen blockade" did not improve time to progression (TTP) in patients with advanced breast cancer, compared with aromatase inhibitor monotherapy with letrozole (Femara).